Hi, I am Johann Hofmann, My LiveDNA is 43.6033
 
   
  Home
 
 
 
Dr. Johann Hofmann
 
Highest Degree: Ph.D. in Medical Biochemistry from Innsbruck Medical University, Austria
 
Institute: Innsbruck Medical University, Austria
 
Area of Interest: Pharmacology and Toxicology
  •   Pharmacology
  •   Biochemistry
  •   Cancer Pharmacology
  •   Medical Toxicology
 
URL: http://livedna.org/43.6033
 
My SELECTED Publications
1:   Conseil, G., J.M. Perez-Victoria, J.M. Jault, F. Gamarro, A. Goffeau, J. Hofmann and A. di Pietro, 2001. Protein kinase C effectors bind to multidrug ABC transporters and inhibit their activity. Biochemistry, 40: 2564-2571.
CrossRef  |  PubMed  |  Direct Link  |  
2:   Doppler, W., J. Hofmann, H. Oberhuber, K. Maly and H. Grunicke, 1985. Nitrogen mustard interference with potassium transport systems in Ehrlich ascites tumor cells. J. Cancer Res. Clin. Oncol., 110: 35-41.
CrossRef  |  PubMed  |  Direct Link  |  
3:   Doppler, W., J. Hofmann, K. Maly and H. Grunicke, 1987. Amiloride and 5-N, N-dimethylamiloride inhibit the carrier mediated uptake of choline in Ehrlich ascites tumor cells. Biochem. Pharmacol., 36: 1645-1649.
CrossRef  |  PubMed  |  Direct Link  |  
4:   Doppler, W., J. Hofmann, K. Maly and H.H. Grunicke, 1988. Protection of Ehrlich ascites tumor cells against the antiproliferative effect of mechlorethamine (nitrogen mustard) by 5-N,N-dimethylamiloride. Cancer Res., 48: 2454-2457.
PubMed  |  Direct Link  |  
5:   Easmon, J., G. Heinisch, G. Purstinger, T. Langer, J.K. Osterreicher, H.H. Grunicke and J. Hofmann, 1997. Azinyl and diazinyl hydrazones derived from aryl N-heteroaryl ketones: Synthesis and antiproliferative activity. J. Med. Chem., 40: 4420-4425.
CrossRef  |  PubMed  |  Direct Link  |  
6:   Easmon, J., G. Heinisch, J. Hofmann, T. Langer, H.H. Grunicke, J. Fink and G. Pirstinger, 1997. Thiazoyl and benzothiazoyl hydrazones derived from-(N)-acetylpyridines and diazines: Synthesis, antiproliferative activity and CoMFA studies. Eur. J. Med. Chem., 32: 397-408.
7:   Easmon, J., G. Puerstinger, T. Roth, H.H. Fiebig and M. Jenny et al., 2001. 2-benzoxazolyl and 2-benzimidazolyl hydrazones derived from 2-acetylpyridine: A novel class of antitumor agents. Int. J. Cancer, 94: 89-96.
CrossRef  |  PubMed  |  Direct Link  |  
8:   Easmon, J., G. Purstinger, G. Heinisch, T. Roth and H.H. Fiebig et al., 2001. Synthesis, cytotoxicity, and antitumor activity of copper(II) and iron(II) complexes of 4N-azabicyclo[3.2.2]nonane thiosemicarbazones derived from acyl diazines. J. Med. Chem., 44: 2164-2171.
CrossRef  |  PubMed  |  Direct Link  |  
9:   Easmon, J., G. Purstinger, K.S. Thies, G. Heinisch and J. Hofmann, 2006. Synthesis, structure-activity relationships, and antitumor studies of 2-benzoxazolyl hydrazones derived from alpha-(N)-acyl heteroaromatics. J. Med. Chem., 49: 6343-6350.
CrossRef  |  PubMed  |  Direct Link  |  
10:   Florian, R., P. Gruber, J. Hofmann and J. Kirchmair, 2011. Modulators of Protein-protein interactions-novel approaches in targeting protein kinases and other pharmaceutically relevant biomolecules. Curr. Top. Med. Chem., 11: 1305-1319.
CrossRef  |  PubMed  |  
11:   Garczarczyk, D., E. Toton, V. Biedermann, E. Rosivatz, F. Rechfeld, M. Rybczynska and J. Hofmann, 2009. Signal transduction of constitutively active protein kinase C epsilon. Cell. Signalling, 21: 745-752.
CrossRef  |  PubMed  |  Direct Link  |  
12:   Garczarczyk, D., F. Rechfeld, G. Hechenberger and J. Hofmann, 2006. Protein kinase C isozymes-targets for potential therapies. DOSIS, 22: 93-103.
13:   Garczarczyk, D., K. Szeker, P. Galfi, A. Csordas and J. Hofmann, 2010. Protein kinase Cγ in colon cancer cells: Expression, Thr514 phosphorylation and sensitivity to butyrate-mediated upregulation as related to the degree of differentiation. Chemico-Biol. Interact., 185: 25-32.
CrossRef  |  PubMed  |  Direct Link  |  
14:   Gekeler, V., R. Boer, F. Uberall, W. Ise and C. Schubert et al., 1996. Effects of the selective bisindolylmaleimide protein kinase C inhibitor GF 109203X on P-glycoprotein-mediated multidrug resistance. Br. J. Cancer, 74: 897-905.
PubMed  |  
15:   Gruber, P., F. Rechfeld, J. Kirchmair, N. Hauser and M. Boehler et al., 2011. Barbituric acid derivative BAS 02104951 inhibits PKCε, PKCη, PKCε/RACK2 interaction, Elk-1 phosphorylation in HeLa and PKCΕ and η translocation in PC3 cells following TPA-induction. J. Biochem., 149: 331-336.
CrossRef  |  PubMed  |  Direct Link  |  
16:   Grunicke, H. and J. Hofmann, 1992. Cytotoxic and cytostatic effects of antitumor agents induced at the plasma membrane level. Pharmacol. Ther., 55: 1-30.
CrossRef  |  PubMed  |  Direct Link  |  
17:   Grunicke, H., J. Hofmann and I. Utz, 1994. Role of protein kinases in antitumor drug resistance. Ann. Hematol., 69: S1-S6.
CrossRef  |  PubMed  |  Direct Link  |  
18:   Grunicke, H., J. Hofmann, K. Maly, F. Uberall, L. Posch, H. Oberhuber and H. Fiebig, 1989. The phospholipid- and Calcium-dependent protein kinase as a target in tumor chemotherapy. Adv. Enzyme Regulat., 28: 201-216.
CrossRef  |  PubMed  |  Direct Link  |  
19:   Grunicke, H., W. Doppler, J. Hofmann, H. Lindner and K. Maly et al., 1985. Plasma membrane as target of alkylating agents. Adv. Enzyme Regulat., 24: 247-261.
CrossRef  |  PubMed  |  Direct Link  |  
20:   Grunicke, H., W. Doppler, S.A.E. Finch, R. Greinert and K. Grunewald et al., 1985. Effects of nitrogen mustard on potassium transport systems and membrane structure of ehrlich ascites tumor cells. Adv. Enzyme Regulat., 23: 277-290.
CrossRef  |  PubMed  |  Direct Link  |  
21:   Grunicke, H., W. Doppler, W. Helliger, B.J. Hermann, J. Hofmann, H. Lindner and B. Puschendorf, 1986. Progress in tumorchemotherapy based on advances in tumorbiochemistry. Arch. Geschwulstforsch, 56: 183-191.
22:   Grunicke, H., W. Helliger, B.J. Hermann, W. Hock, J. Hofmann and B. Puschendorf, 1986. Alkylating antitumor agents reduce histone Acetyl-transferase activity. Adv. Enzyme Regulat., 25: 87-90.
CrossRef  |  PubMed  |  Direct Link  |  
23:   Helliger, W., J. Hofmann, K. Maly, W. Doppler and B.J. Hermann et al., 1988. Differential sensitivity of histone acetylation in nitrogen-mustard sensitive and resistant cells. Relation to drug uptake, formation and repair of DNA-interstrand cross-links. Eur. J. Cancer Clin. Oncol., 24: 1861-1868.
CrossRef  |  PubMed  |  Direct Link  |  
24:   Hofmann, J. and A. Pfitscher, 1982. Changing of microbial activities in alpine soils under ski slopes and foot pathes. Pedobiologia, 23: 105-111.
25:   Hofmann, J. and A. Pfitscher, 1982. Correlations of enzyme-activities in soil. Z. Pflanzenernaehr. Bodenk., 145: 36-41.
26:   Hofmann, J. and C. Ludescher, 1995. Multiple resistenz gegen zytostatika. Berichte OGKC, 18: 153-157.
27:   Hofmann, J., 1997. The potential for Isoenzyme-selective modulation of protein kinase C. FASEB J., 11: 649-669.
PubMed  |  Direct Link  |  
28:   Hofmann, J., 2001. Modulation of Protein Kinase C in Antitumor Treatment. In: Reviews of Physiology, Biochemistry and Pharmacology, Hofmann, J. (Ed.). Springer, Berlin Heidelberg, pp: 1-96.
CrossRef  |  PubMed  |  Direct Link  |  
29:   Hofmann, J., 2001. Protein kinase C und die modulation der multidrug resistenz. Symp. Med. Oncol., 12: 12-13.
30:   Hofmann, J., 2004. Protein kinase C isozymes as potential targets for anticancer therapy. Current Cancer Drug Targets, 4: 125-146.
CrossRef  |  PubMed  |  
31:   Hofmann, J., 2008. Resistance to chemotherapy. Br. J. Cancer, 99: 1368-1368.
CrossRef  |  Direct Link  |  
32:   Hofmann, J., A. Wolf, M. Spitaler, G. Bock, J. Drach, C. Ludescher and H. Grunicke, 1992. Reversal of multidrug resistance by B859-35, a metabolite of B859-35, niguldipine, verapamil and nitrendipine. J. Cancer Res. Clin. Oncol., 118: 361-366.
CrossRef  |  PubMed  |  Direct Link  |  
33:   Hofmann, J., F. Uberall, L. Posch, K. Maly, D.B.J. Herrmann and H. Grunicke, 1989. Synergistic enhancement of the Anti-proliferative activity of Cis-diamminedichloro-platinum(II) by the new ether lipid analogue BM 41 440, an inhibitor of protein kinase C. Lipids, 24: 312-317.
34:   Hofmann, J., F. Ueberall, A.E. And and H. Grunicke, 1991. B-859-35, a new drug with anti-tumor activity reverses Multi-drug resistance. Int. J. Cancer, 47: 870-874.
CrossRef  |  PubMed  |  Direct Link  |  
35:   Hofmann, J., H.H. Fiebig, B.R. Winterhalter, D.P. Berger and H. Grunicke, 1990. Enhancement of the antiproliferative activity of Cis-diamminedichloroplatinum(II) by quercetin. Int. J. Cancer, 45: 536-539.
CrossRef  |  PubMed  |  Direct Link  |  
36:   Hofmann, J., I. Utz, M. Spitaler, S. Hofer and M. Rybczynska et al., 1997. Resistance to the new Anti-cancer phospholipid ilmofosine (BM 41 440). Br. J. Cancer, 76: 862-869.
CrossRef  |  PubMed  |  Direct Link  |  
37:   Hofmann, J., J. Easmon, G. Purstinger, G. Heinisch and D.F. Condorelli et al., 2009. Investigations on the mechanism of action of the new antitumor compound EPH136. Invest. New Drugs, 27: 189-202.
38:   Hofmann, J., P.M. Oconnor, J. Jackman, C. Schubert, F. Ueberall, K.W. Kohn and H. Grunicke, 1994. The protein kinase C inhibitor ilmofosine (BM 41 440) arrests cells in G2 phase and suppresses CDC2 kinase activation through a mechanism different from that of DNA damaging agents. Biochem. Biophys. Res. Commun., 199: 937-943.
CrossRef  |  PubMed  |  Direct Link  |  
39:   Hofmann, J., V. Gekeler, W. Ise, A. Noller and J. Mitterdorfer et al., 1995. Mechanism of action of dexniguldipine-HCl (B8509-035), a new potent modulator of multidrug resistance. Biochem. Pharmacol., 49: 603-609.
CrossRef  |  PubMed  |  Direct Link  |  
40:   Hofmann, J., W. Doppler, A. Jakob, K. Maly, L. Posch, F. Uberall and H.H. Grunicke, 1988. Enhancement of the antiproliferative effect of cis-diamminedichloroplatinum(II) and nitrogen mustard by inhibitors of protein kinase C. Int. J. Cancer, 42: 382-388.
CrossRef  |  PubMed  |  Direct Link  |  
41:   Klocker, H., B. Auer, H.J. Burtscher, J. Hofmann, M. Hirsch-Kauffmann and M. Schweiger, 1982. A sensitive radioimmuno assay for thymine dimers. Mol. General Genet., 186: 475-477.
CrossRef  |  PubMed  |  Direct Link  |  
42:   Lamy, C., J. Hofmann, H. Parrot-Lopez and P. Goekjian, 2007. Synthesis of a fluoroalkene peptidomimetic precursor of N-acetyl-l-glutamyl-l-alanine. Tetrahedron Lett., 48: 6177-6180.
CrossRef  |  Direct Link  |  
43:   Ludescher, C., J. Drach, J. Hofmann and H. Grunicke, 1991. Rapid functional assay for the detection of multidrug-resistant cells using the fluorescent dye rhodamine 123 [letter; comment]. Blood, 78: 1385-1387.
PubMed  |  Direct Link  |  
44:   Ludescher, C., J. Thaler, D. Drach, J. Drach and M. Spitaler et al., 1992. Detection of activity of P-glycoprotein in human tumour samples using rhodamine 123. Br. J. Haematol., 82: 161-168.
CrossRef  |  PubMed  |  Direct Link  |  
45:   Ludescher, C., W. Eisterer, W. Hilbe, J. Hofmann and J. Thaler, 1995. Decreased potency of MDR-modulators under serum conditions determined by a functional assay. Br. J. Haematol., 91: 652-657.
CrossRef  |  PubMed  |  Direct Link  |  
46:   Ludescher, C., W. Eisterer, W. Hilbe, M. Gotwald and J. Hofmann et al., 1995. Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukemia compared to acute myeloid leukemia. Leukemia, 9: 350-356.
PubMed  |  
47:   Ludescher, C., W. Hilbe, W. Eisterer, E. Preuβ and C. Huber et al., 1993. Activity of P-glycoprotein in B-cell chronic lymphocytic leukemia determined by a flow cytometric assay. J. Natl. Cancer Inst., 85: 1751-1758.
CrossRef  |  PubMed  |  Direct Link  |  
48:   Ludescher, C., W. Hilbe, W. Eisterer, E. Preuβ, J. Hofmann and J. Thaler, 1994. Funktionelle erfassung P-glykoprotein-exprimierender zellen mittels durchflusszytometrie. Wiener Klin. Wochenschr., 106: 242-246.
49:   Ludescher, C., W. Hilbe, W. Eisterer, J. Thaler, M. Gotwald and J. Hofmann, 1993. Low incidence of activity of P-glycoprotein (P-170) in de novo acute lymphoblastic leukemia determined by a flow cytometric assay. Blood, 82: 3505-3507.
PubMed  |  Direct Link  |  
50:   Maly, K., W. Doppler, H. Oberhuber, H. Meusburger, J. Hofmann, R. Jaggi and H.H. Grunicke, 1988. Desensitization of the Ca2+-mobilizing system to serum growth factors by Ha-ras and v-mos. Mol. Cell. Biol., 8: 4212-4216.
PubMed  |  Direct Link  |  
51:   Margesin, R., H. Dieplinger, J. Hofmann, B. Sarg and H. Lindner, 2005. A Cold-active extracellular metalloprotease from Pedobacter cryoconitis-production and properties. Res. Microbiol., 156: 499-505.
CrossRef  |  PubMed  |  Direct Link  |  
52:   Mwanjewe, J., M. Spitaler, M. Ebner, M. Windegger and M. Geiger et al., 2001. Regulation of phospholipase D isoenzymes by transforming Ras and atypical protein kinase C-i. Biochem. J., 359: 211-217.
Direct Link  |  
53:   Ol'shevskaya, V.A., A.V. Zaitsev, V.N. Luzgina, T.T. Kondratieva and O.G. Ivanov et al., 2006. Novel boronated derivatives of 5,10,15,20-tetraphenylporphyrin: Synthesis and toxicity for drug-resistant tumor cells. Bioorganic Med. Chem., 14: 109-120.
CrossRef  |  PubMed  |  Direct Link  |  
54:   Pall, G., M. Spitaler, J. Hofmann, J. Thaler and C. Ludescher, 1997. Multidrug resistance in acute leukemia: A comparison of different diagnostic methods: Phenotypic and genotypic analyses of multidrug resistance (MDR) in clinical hospital practice. Leukemia, 11: 1067-1072.
55:   Paszel, A., B. Blazej Rubis, B. Barbara Bednarczyk-Cwynar, L. Lucjusz Zaprutko, M. Mariusz Kaczmarek, J. Hofmann and M. Maria Rybczynska, 2012. The oleanolic acid derivative methyl 3,11-dioxoolean-12-en-28-olate targets multidrug resistance related to ABCB1. Pharmacol. Rep., 63: 1500-1517.
PubMed  |  Direct Link  |  
56:   Perkhofer, S., B.E. Kehrel, M.P. Dierich, J.P. Donnelly and W. Nussbaumer et al., 2008. Human platelets attenuate Aspergillus species via Granule-dependent mechanisms. J. Infecti. Dis., 198: 1243-1246.
CrossRef  |  PubMed  |  Direct Link  |  
57:   Radford, D.J., K. Wang, J.C. McNelis, A.E. Taylor and G. Hechenberger et al., 2010. Dehydroepiandrosterone sulfate directly activates protein kinase C-β to increase human neutrophil superoxide generation. Mol. Endocrinol., 24: 813-821.
CrossRef  |  PubMed  |  Direct Link  |  
58:   Rybczynska, M., M. Spitaler, N.G. Knebel, G. Boeck, H. Grunicke and J. Hofmann, 2001. Effects of miltefosine on various biochemical parameters in a panel of tumor cell lines with different sensitivities. Biochem. Pharmacol., 62: 765-772.
CrossRef  |  PubMed  |  Direct Link  |  
59:   Rybczynska, M., R. Liu, P. Lu, F.J. Sharom and E. Steinfels et al., 2001. MDR1 causes resistance to the antitumour drug miltefosine. Br. J. Cancer, 84: 1405-1411.
CrossRef  |  PubMed  |  Direct Link  |  
60:   Shishkin, A.A., O.G. Ivanov, A.V. Zaitsev, E.G. Kononova and E.A. Malinina et al., 2005. The Copper-containing monocarboranylporphyrin: A prototype of new DNA-binding cytotoxic compounds. Doklady Biochem. Biophys., 403: 313-316.
CrossRef  |  PubMed  |  Direct Link  |  
61:   Spitaler, M., B. Wiesenhofer, V. Biedermann, T. Seppi, J. Zimmermann, H. Grunicke and J. Hofmann, 1999. The involvement of protein kinase C isoenzymes alpha, epsilon and zeta in the sensitivity to antitumor treatment and apoptosis induction. Anticancer Res., 19: 3969-3976.
PubMed  |  
62:   Spitaler, M., I. Utz, W. Hilbe, J. Hofmann and H.H. Grunicke, 1998. PKC-independent modulation of Multidrug resistance in cells with mutant (V185) but not wild-type (G185) P-glycoprotein by bryostatin 1. Biochem. Pharmacol., 56: 861-869.
CrossRef  |  PubMed  |  Direct Link  |  
63:   Toton, E., N. Lisiak, B. Rubis, J. Budzianowski, P. Gruber, J. Hofmann and M. Rybczynska, 2012. The tetramethoxyflavone zapotin selectively activates protein kinase C epsilon, leading to its Down-modulation accompanied by Bcl-2, c-Jun and c-Fos decrease. Eur. J. Pharmacol., 682: 21-28.
CrossRef  |  PubMed  |  Direct Link  |  
64:   Uberall, F., K. Maly, A. Egle, W. Doppler, J. Hofmann and H.H. Grunicke, 1991. Inhibition of cell proliferation, protein kinase C and phorbol Ester-induced fos expression by the dihydropyridine derivative B859-35. Cancer Res., 51: 5821-5825.
PubMed  |  Direct Link  |  
65:   Utz, I., M. Spitaler, M. Rybczynska, C. Ludescher, W. Hilbe, U. Regenass, H. Grunicke and J. Hofmann, 1998. Reversal of multidrug resistance by the staurosporine derivatives CGP 41251 and CGP 42700. Int. J. Cancer, 77: 64-69.
PubMed  |  Direct Link  |  
66:   Utz, I., S. Hofer, U. Regenass, W. Hilbe, J. Thaler, H. Grunicke and J. Hofmann, 1994. The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance. Int. J. Cancer, 57: 104-110.
CrossRef  |  PubMed  |  Direct Link  |  
67:   Utz, I., V. Gekeler, W. Ise, J. Beck, M. Spitaler, H. Grunicke and J. Hofmann, 1995. Protein kinase C isoenzymes, p53, accumulation of rhodamine 123, glutathione-S-transferase, topoisomerase II and MRP in multidrug resistant cell lines. Anticancer Res., 16: 289-296.
PubMed  |  Direct Link  |